10-Sep-2026
27.65
-0.13 {-0.5 %}
V: 27,622,286
PFE
10-Sep-2026
Close: 27.65
-0.13 {-0.5 %}
Volume: 27,622,286
26-Aug-2026
02-Jul-2026
30-Sep-2024
30-Sep-2019
PFE
SPY
-0.5
-2.8
-2.8
14.8
11.0
-0.6
-1.6
-1.2
1.5
11.1
% Price Gain
WTD Performance (%)
MTD Performance (%)
QTD Performance (%)
YTD Performance (%)
SPY tracks S&P 500 index.
15 minute intraday candlestick chart, ~15 minute delay
15 minute intraday candlestick chart, ~15 minute delay
PFE News
10-Sep-2026 - Seeking AlphaPfizer: Firing On All Cylinders Pfizer's pipeline strength is evident, especially with berobenatide and Vyndamax, providing a bridge over the 2028 LOE trough ... 8-Sep-2026 - The Motley FoolMove aside, Pfizer: This stock is the smarter dividend buy right now Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior. 8-Sep-2026 - Yahoo FinanceNovartis India acquires Pfizer brands for $132m "Novartis India acquires Pfizer brands for $132m" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. 6-Sep-2026 - Business TodayNovartis India shares jump 4% on Rs 1,250 crore Pfizer trademarks acquisition Novartis India said its board approved the transaction at a meeting held on September 7. The company subsequently executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc. 5-Sep-2026 - The Globe and MailPfizer Steps Up in Obesity Race With New Phase 3 Berobenatide Trial in Japan Pfizer Inc announced an update on their ongoing clinical study. Pfizer Inc. (PFE) has launched a Phase 3 study in Japan called VESPER-JW to test once-weekly berobenatide in adults ... 5-Sep-2026 - The Globe and MailPfizer’s Next Move in Obesity Drugs: What the New VESPER-JM Trial Means for PFE Investors The goal is to see if the drug helps with weight loss while staying safe, a key step as Pfizer tries to build a bigger presence in the fast-growing obesity treatment market. The study tests ... 4-Sep-2026 - AOLPfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying? Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about ... 3-Sep-2026 - Yahoo FinancePfizer (PFE) After FDA Vaccine Approval Faces A Fair Value Reality Check Pfizer (PFE) has drawn fresh attention after the FDA approved its 2026 to 2027 COMIRNATY XFG COVID-19 vaccine formula for ... 3-Sep-2026 - Seeking AlphaPfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugate Pfizer (PFE) and Medicus Pharma (MDCX) sign a licensing deal worth up to $1B for PF-08046031 ("CD228V"), an antibody drug ...
More PFE News
Latest PFE Trades by Congress Members
13-MAR-2026 - Gilbert Cisneros, CA (District 31) sold some (partial sale) valued between $1,001 and $15,000.THIS TRADE WAS FILED 7-APR-2026.
10-FEB-2026 - Gilbert Cisneros, CA (District 31) purchased between $1,001 and $15,000.THIS TRADE WAS FILED 9-MAR-2026.
31-DEC-2025 - James French Hill, AR (District 2) sold between $100,001 and $250,000.THIS TRADE WAS FILED 23-JAN-2026.
19-DEC-2025 - Gilbert Cisneros, CA (District 31) sold some (partial sale) valued between $1,001 and $15,000.THIS TRADE WAS FILED 12-JAN-2026.
18-NOV-2025 - Gilbert Cisneros, CA (District 31) purchased between $1,001 and $15,000.THIS TRADE WAS FILED 15-DEC-2025.
Latest PFE Trades by Congress Members
13-MAR-2026 - Gilbert Cisneros, CA (District 31) sold some (partial sale) valued between $1,001 and $15,000.THIS TRADE WAS FILED 7-APR-2026.
10-FEB-2026 - Gilbert Cisneros, CA (District 31) purchased between $1,001 and $15,000.THIS TRADE WAS FILED 9-MAR-2026.
31-DEC-2025 - James French Hill, AR (District 2) sold between $100,001 and $250,000.THIS TRADE WAS FILED 23-JAN-2026.
19-DEC-2025 - Gilbert Cisneros, CA (District 31) sold some (partial sale) valued between $1,001 and $15,000.THIS TRADE WAS FILED 12-JAN-2026.
18-NOV-2025 - Gilbert Cisneros, CA (District 31) purchased between $1,001 and $15,000.THIS TRADE WAS FILED 15-DEC-2025.
More PFE Congress Trades
Disclaimer
Privacy
Contact
Copyright © 2001-2026, All rights reserved. HotCandlestick.com, LLC